Latest European Manufacturing News

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

Titomic Limited has launched a major European manufacturing hub and a UK subsidiary, secured a $50 million capital raise, and forged strategic partnerships to advance its cold spray additive manufacturing technology.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

Reliance Worldwide Corporation reports a solid 5.5% sales increase and a 13.5% rise in net profit for FY25, boosted by the Holman acquisition, while cautioning on tariff impacts ahead.

Vection Technologies has reported its first positive underlying EBITDA for FY2025, driven by strong growth in its Defence sector. The company sets ambitious FY2026 revenue targets of $70 million, underpinned by a robust $50 million sales pipeline and cutting-edge AI and spatial computing solutions.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

AML3D Limited reports a 77% jump in US customer receipts and secures a pivotal US Navy Letter of Intent worth up to $200 million, underpinning its rapid expansion in defence manufacturing.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

DroneShield Limited has reported a record-breaking first quarter with $33.5 million in revenue, more than doubling year-over-year, supported by a robust $94.4 million in committed purchase orders and a burgeoning SaaS segment. The company’s expansive $1.6 billion sales pipeline and strong cash position set the stage for accelerated growth in the counter-unmanned systems market.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with imminent UK export approvals and planned European manufacturing.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.